All In Biotech

Drug Trial Radar · NCT04089631

Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation

Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (CIRCULATE) AIO-KRK-0217

Last checked: Nov 19, 2026Latest source record: Aug 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 4,812 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

4,812

Planned (sponsor's estimate)

Start

Jun 26, 2020

Primary completion

Jun 2023

Study completion Jun 2026

Sponsor

Lead sponsor
Technische Universität DresdenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CIRCULATE study evaluates the adjuvant therapy in patients with colon cancer UICC stage II. The primary aim of the study is to compare the disease free survival in patients who are positive for postoperative circulating tumour DNA with vs. without capecitabine.

Conditions

  • Colon Cancer Stage II

Interventions

  • CapecitabineDrug

    6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease free Survival (DFS)Time frame: for the primary endpoint after 154 events (approx. 60 months after study start)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Universitaetsklinikum Carl Gustav Carus, Medizinische Klinik

    Dresden, Saxony, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.